Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
776.100.03%
QQQ
731.000.01%
BTC/USD
62790.371.0011%
DIA
536.960.03%
GLD
401.790.08%
TLT
82.04-

TuHURA Biosciences Inc (HURA) Stock Price, Quote, News & History

HURANASDAQ
Trade with Public
Trade with Public
$2.47
0.177.39%
At close: Aug 14, 5:00 PM EST
$2.26
-0.21-8.5%
After Hours: 8:02 AM EST
Earnings: Q2 2026 earnings were released today before the market open
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Key Statistics

Open
$2.29
Close
$2.47
Volume / Avg.
317.09K / 492.87K
Day Range
$2.22 - $2.49
52 Wk Range
0.41 - 3.43
Market Cap
$143.92M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
64
Short Interest
13.25%
Days to Cover
31.85

Recent TuHURA Biosciences Inc News

PRO
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share
Benzinga Newsdesk

PRO
TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an
Benzinga Newsdesk

PRO
TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share
Benzinga Newsdesk

PRO
Citizens Initiates Coverage On TuHURA Biosciences with Market Outperform Rating, Announces Price Target of $9

Citizens analyst Silvan Turkcan initiates coverage on TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
TuHURA Biosciences Enters Loan Agreement For Credit Facility Of Up To $50M For Its Pipeline, Ongoing Clinical Trials And General Corporate Expenses

The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC. Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis
Benzinga Newsdesk

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-27.30M
Investing Cash Flow (TTM)
-233.16K
Financing Cash Flow (TTM)
27.62M
Free Cash Flow (TTM)
-27.39M
Capital Expenditure (TTM)
-82.26K
Net Change in Cash (TTM)
78.30K

Analyst Trends and Forecast

0
0
0
0
Apr
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$140.91M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
6.39
Earnings Yield % (TTM)
-26.52%
Earnings Yield % (FWD)
-25.43%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.36

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$2.59M
Total Cash
$6.30M
Debt to Equity
0.02
Issuance of Debt (TTM)
$408.78K
Repayment of Debt (TTM)
-$2.59M

Key Statistics

Open
$2.29
Close
$2.47
Volume / Avg.
317.09K / 492.87K
Day Range
$2.22 - $2.49
52 Wk Range
0.41 - 3.43
Market Cap
$143.92M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
64
Short Interest
13.25%
Days to Cover
31.85

About

Sector
Health Care
Industry
Biotechnology
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy TuHURA Biosciences (HURA) stock?

A

You can purchase shares of TuHURA Biosciences (NASDAQ:HURA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TuHURA Biosciences (HURA) competitors?

Q

What is the forecast, or price target, for TuHURA Biosciences (HURA) stock?

A

TuHURA Biosciences has a consensus price target of $9.50.

Q

What is the current price for TuHURA Biosciences (HURA)?

A

The stock price for TuHURA Biosciences (NASDAQ: HURA) is $2.26 last updated August 14, 2026 at 8:02 AM EDT.

Q

Does TuHURA Biosciences (HURA) pay a dividend?

A

There are no upcoming dividends for TuHURA Biosciences.

Q

When is TuHURA Biosciences (NASDAQ:HURA) reporting earnings?

A

TuHURA Biosciences does not have any upcoming earnings scheduled.

Q

Is TuHURA Biosciences (HURA) going to split?

A

There is no upcoming split for TuHURA Biosciences.

Q

What sector and industry does TuHURA Biosciences (HURA) operate in?

A

TuHURA Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved